Stockscreener 앱 받기
6.15
3.15%
-0.20
전일 마감가:
$6.35
열려 있는:
$6.48
하루 거래량:
633.24K
Relative Volume:
0.74
시가총액:
$419.74M
수익:
$46.02M
순이익/손실:
$-70.80M
주가수익비율:
-3.3791
EPS:
-1.82
순현금흐름:
$-1.61M
1주 성능:
-5.38%
1개월 성능:
-19.40%
6개월 성능:
-32.04%
1년 성능:
-76.91%
1일 변동 폭
$6.05
$6.55
1주일 범위
$6.05
$7.59
52주 변동 폭
$5.90
$29.31
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
명칭
Eyepoint Pharmaceuticals Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
EYPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
6.15 | 419.74M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Pharmaceuticals Inc 주식(EYPT)의 최신 뉴스
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates - MSN
Adversity is less terrifying than hope: EyePoint Pharmaceuticals Inc (EYPT) - SETE News
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Grants Stock Options to New Employees as Inducement Awards - Nasdaq
(EYPT) Trading Advice - Stock Traders Daily
230,745 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Bought by abrdn plc - MarketBeat
TD Cowen maintains EyePoint stock Buy rating, $20 target - MSN
Brokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Target Price at $26.63 - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Earns "Buy" Rating from Chardan Capital - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 52-Week LowTime to Sell? - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Earns Buy Rating from Chardan Capital - Armenian Reporter
EyePoint's decline following positive data makes no sense, says analyst - MSN
EyePoint Pharmaceuticals Inc [EYPT] Shares Fall Approximately -76.18% Over the Year - Knox Daily
EyePoint Pharmaceuticals (NASDAQ:EYPT) Receives Buy Rating from Chardan Capital - Armenian Reporter
Investors unsure on EyePoint’s Duravyu blockbuster claim - The Pharma Letter
A significant driver of top-line growth: EyePoint Pharmaceuticals Inc (EYPT) - SETE News
There Is A Lot Of Upside Potential For EyePoint Pharmaceuticals Inc(NASDAQ: EYPT) - Stocks Register
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of “Buy” by Analysts - ETF Daily News
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts - Defense World
EyePoint stock jumps 10% on Duravyu study results - MSN
(EYPT) Investment Analysis - Stock Traders Daily
Analyzing the Impact of Earnings Reports on EyePoint Pharmaceuticals Inc Inc. (EYPT) Price Performance - The InvestChronicle
Short Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Rises By 9.9% - MarketBeat
EyePoint Pharmaceuticals : Investor Presentation February 2025 - Marketscreener.com
EyePoint stock jumps 10% on Duravyu study results (EYPT:NASDAQ) - Seeking Alpha
EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell - Marketscreener.com
Collegium Appoints Nancy S. Lurker to its Board of Directors - citybiz
EyePoint’s decline following positive data makes no sense, says analyst By Investing.com - Investing.com Nigeria
EyePoint's decline following positive data makes no sense, says analyst By Investing.com - Investing.com South Africa
Pharma Veteran Nancy Lurker Joins Collegium Board: Ex-Novartis CMO Brings M&A Expertise - StockTitan
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints - The Manila Times
EyePoint Pharmaceuticals stock sinks following clinical trial results By Investing.com - Investing.com South Africa
Should investors be concerned about EyePoint Pharmaceuticals Inc (EYPT)? - US Post News
EyePoint Pharmaceuticals stock sinks following clinical trial results - Investing.com
Clinical Trial Success: EyePoint's DME Drug Reduces Treatment Burden by Two-Thirds - StockTitan
Analyzing EyePoint Pharmaceuticals Inc (EYPT) After Recent Trading Activity - Knox Daily
Financial Health Report: EyePoint Pharmaceuticals Inc (EYPT)’s Ratios Tell a Tale - The Dwinnex
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Update - Defense World
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival (NASDAQ:EYPT) - Seeking Alpha
EyePoint Pharmaceuticals' CEO Jay S. Duker to Speak at Guggenheim SMID Cap Biotech Conference on February 6, 2025 - Nasdaq
EyePoint to Present at Guggenheim SMID Cap Biotech Conference - The Manila Times
Inside EyePoint's Strategy: CEO Set to Reveal Latest Developments in Retinal Disease Treatment - StockTitan
Franklin Resources Inc. Expands Portfolio with EyePoint Pharmace - GuruFocus.com
Long Term Trading Analysis for (EYPT) - Stock Traders Daily
Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss - Yahoo Finance
Brokers Offer Predictions for EYPT FY2025 Earnings - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 6.1% HigherShould You Buy? - MarketBeat
Research Analysts Issue Forecasts for EYPT FY2025 Earnings - MarketBeat
Eyepoint Pharmaceuticals Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Eyepoint Pharmaceuticals Inc 주식 (EYPT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lurker Nancy | Director |
Feb 09 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
205,436 |
| Duker Jay S. | President and CEO |
Feb 09 '25 |
Option Exercise |
0.00 |
7,000 |
0 |
79,706 |
| Elston George | Chief Financial Officer |
Jan 06 '25 |
Option Exercise |
0.00 |
15,285 |
0 |
73,374 |
| Elston George | Chief Financial Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
15,000 |
0 |
63,356 |
| Lurker Nancy | Director |
Jan 06 '25 |
Option Exercise |
0.00 |
75,134 |
0 |
185,436 |
| Lurker Nancy | Director |
Jan 05 '25 |
Option Exercise |
0.00 |
12,667 |
0 |
110,302 |
| Landis John B. | Director |
Jan 05 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
21,400 |
| Duker Jay S. | President and CEO |
Jan 06 '25 |
Option Exercise |
0.00 |
20,794 |
0 |
78,814 |
| Duker Jay S. | President and CEO |
Jan 05 '25 |
Option Exercise |
0.00 |
30,000 |
0 |
68,027 |
0.27%
3.05%
자본화:
|
볼륨(24시간):